Prognostic factors and a new scoring system for survival of patients irradiated for bone metastases

BMC Cancer

Table 2 Univariate analyses of survival

	Survival rate at 6 months (%)	Survival rate at 12 months (%)	p-value
Age
≤ 60 years	61	48
61–70 years	60	44
> 70 years	60	38	0.052
Gender
Female	64	50
Male	56	35	< 0.001
Karnofsky performance score
≤ 70	42	23
80–100	70	55	< 0.001
Type of primary tumor
Breast cancer	78	64
Prostate cancer	78	52
Lung cancer	46	30
Renal cell carcinoma	79	63
Colorectal cancer	45	25	< 0.001
Other tumors	42	22
Interval between cancer diagnosis and RT of bone metastases
≤ 8 months	54	40
≥ 9 months	66	45	0.044
Visceral metastases at the time of RT
No	67	49
Yes	55	38	0.002
Other (non-irradiated) bone metastases at the time of RT
No	53	36
Yes	63	45	0.23
Location of irradiated bone metastases
Spinal site(s) only	59	40
Extraspinal site(s) with or without spinal site(s)	61	44	0.95
Number of irradiated sites
Single	59	43
Multiple	61	42	0.41
Pathological fracture
No	61	46
Yes	57	35	0.049
Pre-RT surgery (no vs. yes)
No	57	42
Yes	72	48	0.17
Pre-RT administration of bisphosphonates/denosumab
No	56	41
Yes	65	45	0.55
Pre-RT systemic anticancer treatment
No	55	40
Yes	62	44	0.33
Fractionation of RT
Short-course RT	40	26
Longer-course RT	62	45	0.022

ISSN: 1471-2407